Rocavorexant

Rocavorexant (INNTooltip International Nonproprietary Name; developmental code names C4X-3256 and INDV-2000) is an orexin OX₁ receptor antagonist which is under development for the treatment of opioid-related disorders and other substance-related disorders.^[1][2][3][4] It is taken orally.^[1] The drug is under development by C4X Discovery and/or Indivior.^[1][2] As of May 2026, development for all indications has been suspended.^[1] The drug has reached phase 2 clinical trials for opioid-related disorders and phase 1 trials for substance-related disorders.^[1][2][4]

Other namesC4X-3256; C4X3256; INDV-2000; INDV2000

Routes of
administrationOral^[1]

Drug classOrexin OX₁ receptor antagonist

CAS Number

• 2115665-09-1

Quick facts Clinical data, Other names ...

Rocavorexant

Clinical data
Other names	C4X-3256; C4X3256; INDV-2000; INDV2000
Routes of administration	Oral[1]
Drug class	Orexin OX1 receptor antagonist
Identifiers
IUPAC name N,6-dimethyl-3-(triazol-2-yl)-N-[(2S)-1-[[5-(trifluoromethyl)pyrazin-2-yl]amino]propan-2-yl]pyridine-2-carboxamide
CAS Number	2115665-09-1
PubChem CID	130295635
ChemSpider	133325612
UNII	8RJN30TJM6
KEGG	D13324
Chemical and physical data
Formula	C18H19F3N8O
Molar mass	420.400 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC(=C(C=C1)N2N=CC=N2)C(=O)N(C)[C@@H](C)CNC3=NC=C(N=C3)C(F)(F)F
InChI InChI=1S/C18H19F3N8O/c1-11-4-5-13(29-25-6-7-26-29)16(27-11)17(30)28(3)12(2)8-23-15-10-22-14(9-24-15)18(19,20)21/h4-7,9-10,12H,8H2,1-3H3,(H,23,24)/t12-/m0/s1 Key:KYPYNXQQCRWPBB-LBPRGKRZSA-N

Close